Discordance in the HER2 status between the primary tumor and CTCs or DTCs included patients in whom the primary tumor was HER2+, but HER2+ CTCs or DTCs were not detected and patients in whom the primary tumor was HER2−, but the CTCs or DTCs were positive for HER2 gene amplification. This evidence concerns the gene ERBB2 and neoplasm.